复方雷公藤汤对肾病大鼠肝脏减毒增效作用的实验研究
|
摘要
目的:借助复方雷公藤汤及其拆方对肾病大鼠的干预效应,考察雷公藤不同配伍对雷公藤的减毒增效作用;筛取治疗肾病综合征毒效关系最优化的中药小复方。方法:大鼠尾静脉注射阿霉素,复制微小病变肾病综合征模型。以复方雷公藤汤及其拆方实施干预,以强地松做阳性对照,检测生化指标、组织病理学指标。结果:与模型公藤组24 h尿蛋白(92.60±18.124 3)相比较,全方组(48.60±11.749 2)、雷芪组(53.20±13.206 1)、雷甘组(56.40±16.520)降低24 h尿蛋白;全方组TP 68.47±5.250 4、ALB 28.97±3.009 3、雷芪组TP 68.21±4.191 27、ALB 27.58±2.618 2、雷甘组TP 67.51±5.420 8、ALB 26.56±1.898 1与模型公藤组TP 58.98±4.8401、ALB 20.98±3.493 4均升高TP、ALB,与模型公藤组chol 1.487 0±0.647 1、TG 1.704 0±1.582 4相比较,全方组chol 0.786 0±0.134 4、TG 0.557 0±0.138 7、雷芪组chol 0.70±0.129 7、TG 0.650 9±0.120 3、雷甘组chol0.974 0±0.328 9、TG 0.668 0±0.184 5均降低;与模型公藤组AST 133.2±7.871 2、ALT 62.60±7.919 0相比较,全方组AST 72.70±10.144 0、ALT 41.80±8.966 6、雷甘组AST 84.20±5.633 2、ALT 38.20±5.846 2、雷金组AST 115.50±9.686 8、ALT 66.10±9.596 9、雷归组AST 128.7±10.739 9、ALT 61.60±8.821 7;差异显著(均P<0.05)。雷公藤不同配伍组对肾脏组织形态学、超微结构上较对照组病理损害有不同程度减轻。全方组、雷甘组、雷何组肝脏组织形态学、超微结构上较对照组病理损害有不同程度减轻。结论:全方组、雷芪组、雷甘组起到增效作用。全方组、雷甘组、雷何组可减低雷公藤肝脏毒性。
Objective: To observe the intervention on attenuation synergistic action of Compound Tripterygium Wilfordii Decoction and its demolition of nehpritis rats and screen the most optimized Chinese medicine small compound for nephrotic syndrome. Methods: By intravenously injecting doxorubicin into rats tails,we copied the minimal change nephrotic syndrome model. The models were intervened by Compound Tripterygium Wilfordii Decoction and its demolition and controlled by prednisone. We tested the chemical and biological indicators and histopathological indicators. Results: Compared with the model group 's 24-hour urine protein( 92. 60 ± 18. 124 3),the whole formula group 's 48. 60 ±11. 749 2,Leiqi group's 53. 20 ± 13. 206 1,Leigan group's 56. 40 ± 6. 520 were reduced. The whole formula group's TP 68. 47 ± 5. 250 4 and ALB 28. 97 ± 3. 009 3,Leiqi group's TP 68. 21 ± 4. 191 27 and ALB 27. 58 ± 2. 618 2,Leigan group's TP 67. 51 ± 5. 420 8 and ALB 26. 56 ± 1. 898 1 were higher than those of the model group's( TP 58. 98 ± 4. 8401,ALB 20. 98 ± 3. 493 4). Compared with the model group's chol 1. 487 0 ± 0. 647 1 and TG 1. 704 0 ± 1. 582 4,the whole formula group's chol 0. 786 0 ± 0. 134 4 and TG 0. 557 0 ± 0. 138 7,Leiqi group's chol 0. 70 ± 0. 129 7 and TG0. 650 9 ± 0. 120 3 and Leigan group's chol 0. 974 0 ± 0. 328 9 and TG 0. 668 0 ± 0. 184 5 were lower. Compared with the model grou's AST 133. 2 ± 7. 871 2 and ALT 62. 60 ± 7. 919 0,the whole formula group's AST 72. 70 ± 10. 144 0 and ALT 41. 80 ± 8. 966 6,Ligan group's AST 84. 20 ± 5. 633 2 and ALT 38. 20 ± 5. 846 2,Leijin group's AST 115. 50± 9. 686 8 and ALT 66. 10 ± 9. 596 9 and Leigui group's AST 128. 7 ± 10. 739 9 and ALT 61. 60 ± 8. 821 7 had significant difference( all P < 0. 05). Tripterygium different compatibility groups ' kidney tissue morphology,ultrastructure pathological lesions were relieved in varying degrees than those of the control group. The whole formula group,Leigan group and Leihe group's liver tissue morphology and ultrastructure pathological lesions were relieved than those of the control group with varying degrees. Conclusion: The whole formula group,Leiqi group and Leigan group had synergism effect. The whole formula group,Leigan group and Leihe group can reduce tripterygium liver toxicity.
Objective: To observe the intervention on attenuation synergistic action of Compound Tripterygium Wilfordii Decoction and its demolition of nehpritis rats and screen the most optimized Chinese medicine small compound for nephrotic syndrome. Methods: By intravenously injecting doxorubicin into rats tails,we copied the minimal change nephrotic syndrome model. The models were intervened by Compound Tripterygium Wilfordii Decoction and its demolition and controlled by prednisone. We tested the chemical and biological indicators and histopathological indicators. Results: Compared with the model group 's 24-hour urine protein( 92. 60 ± 18. 124 3),the whole formula group 's 48. 60 ±11. 749 2,Leiqi group's 53. 20 ± 13. 206 1,Leigan group's 56. 40 ± 6. 520 were reduced. The whole formula group's TP 68. 47 ± 5. 250 4 and ALB 28. 97 ± 3. 009 3,Leiqi group's TP 68. 21 ± 4. 191 27 and ALB 27. 58 ± 2. 618 2,Leigan group's TP 67. 51 ± 5. 420 8 and ALB 26. 56 ± 1. 898 1 were higher than those of the model group's( TP 58. 98 ± 4. 8401,ALB 20. 98 ± 3. 493 4). Compared with the model group's chol 1. 487 0 ± 0. 647 1 and TG 1. 704 0 ± 1. 582 4,the whole formula group's chol 0. 786 0 ± 0. 134 4 and TG 0. 557 0 ± 0. 138 7,Leiqi group's chol 0. 70 ± 0. 129 7 and TG0. 650 9 ± 0. 120 3 and Leigan group's chol 0. 974 0 ± 0. 328 9 and TG 0. 668 0 ± 0. 184 5 were lower. Compared with the model grou's AST 133. 2 ± 7. 871 2 and ALT 62. 60 ± 7. 919 0,the whole formula group's AST 72. 70 ± 10. 144 0 and ALT 41. 80 ± 8. 966 6,Ligan group's AST 84. 20 ± 5. 633 2 and ALT 38. 20 ± 5. 846 2,Leijin group's AST 115. 50± 9. 686 8 and ALT 66. 10 ± 9. 596 9 and Leigui group's AST 128. 7 ± 10. 739 9 and ALT 61. 60 ± 8. 821 7 had significant difference( all P < 0. 05). Tripterygium different compatibility groups ' kidney tissue morphology,ultrastructure pathological lesions were relieved in varying degrees than those of the control group. The whole formula group,Leigan group and Leihe group's liver tissue morphology and ultrastructure pathological lesions were relieved than those of the control group with varying degrees. Conclusion: The whole formula group,Leiqi group and Leigan group had synergism effect. The whole formula group,Leigan group and Leihe group can reduce tripterygium liver toxicity.
引文
[1]孟楣,张静,江莹,等.基于“化学基础”探讨新风胶囊方中雷公藤配伍减毒作用[J].中药材,2016,39(8):1829-1832.
[2]李波,周昕欣,吴美兰,等.雷公藤配伍减毒增效研究与展望[J].中国中西医结合杂志,2006,26(11):1045-1047.
[3]Fernandez-Llama P,Andrews P,Nielsen S,et al.Impairedaquapor 2inandureatransporter expressioninratswithadriamycin-inducenephrotic syndrome[J].Kidney Int,1998,53(5):1244-1253.
[4]彭莉,张林,李品,等.潜在毒性中药探讨[J].中国实验方剂学杂志,2017,23(2):227-233.
[5]李波,吴美兰,周昕欣,等.中药毒性产生的原因及减毒方法[J].中医杂志,2006,47(10):788-789.
[6]曹玲娟,颜苗,李焕德,等.雷公藤致肝损伤及与甘草配伍减毒机制的研究进展[J].中国中药杂志,2015,40(13):2537-2541.
[7]李波,宋顺鹏,史月君.复方雷公藤汤对肾病大鼠血液系统减毒作用的实验研究[J].中国中医急症,2011,20(9):1439.
[8]胡锡琴.制何首乌致肝损害的实验研究[J].陕西中医,2006,27(5):625-626.
[9]覃俏峰.雷公藤的不良反应及中药配伍减毒分析[J].中国当代医药,2011,10(18):96-97.
[10]孙龙,张本永,朱华旭,等.清络通痹精简方中雷公藤异类相制减毒机理的化学基础[J].中国实验方剂学杂志,2017,23(11):83-87.
[11]秦思,李琼,于茜,等.雷公藤多苷配伍黄芪总皂苷对大鼠关节炎的减毒增效作用[J].数理医药学杂志,2016,29(4):540-541.
[12]周玲玲,柳璋璞,冯哲,等.雷公藤复方配伍调控CYP450酶系统减轻肝毒性的研究[J].中华中医药杂志,2016,31(6):2370-2373.
[13]唐利宇,孟楣,张贺,等.基于雷公藤配伍前后雷公藤内酯酮含量变化探讨其减毒机制[J].中国中医药信息杂志,2016,23(8):787-790.
[14]何英蒙,姚媛媛,陈一龙,等.雷公藤类制剂的研究进展[J].中国药房,2017,28(4):551-554.
[15]陶玲,肖芳,朱卫丰,等.雷公藤减毒研究进展[J].中国实验方剂学杂志,2017,23(5):229-234.
[16]金华,石云,刘亚男.中药毒性及减毒方法研究概述[J].天津药学,2015,27(4):56-58.
[17]王嫣然,盛梅笑.中药配伍减轻雷公藤毒性的实验研究进展[J].中华中医药杂志,2016,31(10):4138-4142.
[2]李波,周昕欣,吴美兰,等.雷公藤配伍减毒增效研究与展望[J].中国中西医结合杂志,2006,26(11):1045-1047.
[3]Fernandez-Llama P,Andrews P,Nielsen S,et al.Impairedaquapor 2inandureatransporter expressioninratswithadriamycin-inducenephrotic syndrome[J].Kidney Int,1998,53(5):1244-1253.
[4]彭莉,张林,李品,等.潜在毒性中药探讨[J].中国实验方剂学杂志,2017,23(2):227-233.
[5]李波,吴美兰,周昕欣,等.中药毒性产生的原因及减毒方法[J].中医杂志,2006,47(10):788-789.
[6]曹玲娟,颜苗,李焕德,等.雷公藤致肝损伤及与甘草配伍减毒机制的研究进展[J].中国中药杂志,2015,40(13):2537-2541.
[7]李波,宋顺鹏,史月君.复方雷公藤汤对肾病大鼠血液系统减毒作用的实验研究[J].中国中医急症,2011,20(9):1439.
[8]胡锡琴.制何首乌致肝损害的实验研究[J].陕西中医,2006,27(5):625-626.
[9]覃俏峰.雷公藤的不良反应及中药配伍减毒分析[J].中国当代医药,2011,10(18):96-97.
[10]孙龙,张本永,朱华旭,等.清络通痹精简方中雷公藤异类相制减毒机理的化学基础[J].中国实验方剂学杂志,2017,23(11):83-87.
[11]秦思,李琼,于茜,等.雷公藤多苷配伍黄芪总皂苷对大鼠关节炎的减毒增效作用[J].数理医药学杂志,2016,29(4):540-541.
[12]周玲玲,柳璋璞,冯哲,等.雷公藤复方配伍调控CYP450酶系统减轻肝毒性的研究[J].中华中医药杂志,2016,31(6):2370-2373.
[13]唐利宇,孟楣,张贺,等.基于雷公藤配伍前后雷公藤内酯酮含量变化探讨其减毒机制[J].中国中医药信息杂志,2016,23(8):787-790.
[14]何英蒙,姚媛媛,陈一龙,等.雷公藤类制剂的研究进展[J].中国药房,2017,28(4):551-554.
[15]陶玲,肖芳,朱卫丰,等.雷公藤减毒研究进展[J].中国实验方剂学杂志,2017,23(5):229-234.
[16]金华,石云,刘亚男.中药毒性及减毒方法研究概述[J].天津药学,2015,27(4):56-58.
[17]王嫣然,盛梅笑.中药配伍减轻雷公藤毒性的实验研究进展[J].中华中医药杂志,2016,31(10):4138-4142.